Join
Live feed
·
PRReleasevia Quantisnow
Evogene Ltd logo

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

ByQuantisnow·Wall Street's wire, on your screen.
EVGN· Evogene Ltd
Industrials

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EVGN (Evogene Ltd) and more on Quantisnow.